ABSTRACT
Malignant peripheral nerve sheath tumor (MPNST)
is an uncommon soft tissue malignancy representing approximately 5% of all sarcomas. Half of MPNSTs arise in patients with neurofibromatosis type I (NF1), while about 10% of cases occur in patients with a history of radiation therapy. 1 The remaining 40% of cases arise de novo without known genetic or environmental risk factors. Criteria used to reach a diagnosis of MPNST include a tumor arising from a nerve or preexisting benign nerve sheath tumor and/or ultrastructural or immunohistochemical evidence of Schwann cell differentiation. 2 Given its typical appearance of a fascicular spindle cell neoplasm, a definitive diagnosis of MPNST can be challenging in patients without a suggestive clinical history or absent demonstrable association with a peripheral nerve.
Previous studies have examined the features of MPNST in fine-needle aspiration (FNA) specimens. [3] [4] [5] In these studies, smears tended to be composed of single and clustered spindle cells with oval to "comma"-shaped nuclei and dispersed chromatin without conspicuous nucleoli. The background is often clean with occasional myxoid, collagenous, or fibrillar stromal material. MPNST shows heterologous differentiation in 10% to 15% of cases. 6, 7 The most commonly observed heterologous element is rhabdomyoblastic differentiation (malignant triton tumor), in which case, oval to rounded rhabdomyoblastic cells can be identified on smears or FNA cell blocks. 3, 4 On resection, MPNST is most commonly a fascicular spindle cell neoplasm with areas of alternating hypercellularity and hypocellularity, perivascular accentuation of tumor cells, and variably myxoid to fibrous stroma. Given the diversity of cytologic and histologic features, MPNST can show significant cytomorphologic overlap with many benign and malignant tumors, making definitive diagnosis challenging for patients lacking a suggestive clinical history. 8 Immunohistochemistry has improved our ability to identify cases of MPNST. Still, only 30% to 50% of tumors will express at least one marker of neural differentiation: S100, SOX10, or GFAP. [9] [10] [11] Even when tumors express one of these proteins, the proportion of tumor cells expressing these markers is frequently limited. As a result, establishing evidence of Schwannian differentiation in a cell block or small biopsy specimen can be challenging, if not impossible, given the inherent sampling error associated with both techniques.
In addition to the known role of NF1, TP53, and CDKN2A [12] [13] [14] in the development of MPNST, recent genomic studies have identified recurrent loss-of-function mutations in EED and SUZ12. 15, 16 These mutations were found to be mutually exclusive in NF1-associated, postradiation, and sporadic MPNSTs. EED and SUZ12 encode subunits of the polycomb repressive complex 2 (PRC2), which acts to regulate dimethylation and trimethylation of lysine 27 of histone H3 (H3K27me3). 17 H3K27me3 is a repressive histone modification associated with gene silencing. 18 Beyond MPNST, loss-of-function mutations in the genes encoding subunits of PRC2 have also been identified in myeloid disorders 19, 20 and a subset of leukemias, 21, 22 where they have been shown to upregulate multiple potential oncogenes. 23 Similarly, in MPNST, loss of function mutations in EED and SUZ12 leads to increased expression of various homeobox transcription factors 15 that have been hypothesized to drive tumorigenesis. Previous work has shown that H3K27me3 immunohistochemistry can serve as a surrogate marker for loss-offunction mutations in EED or SUZ12 15 and that loss of H3K27me3 staining can be used as a diagnostic marker of MPNST in surgical specimens. [24] [25] [26] We sought to examine the utility of H3K27me3 immunohistochemistry as an ancillary discriminatory test for MPNST in cell block and small biopsy specimens.
Materials and Methods
The cytology and general surgical files of the Brigham and Women's Hospital (Boston, MA) were searched for FNA (with available cell blocks) and small biopsy specimens of MPNST and cytomorphologic mimics. This search identified 180 cases, including 66 cell blocks and 114 small biopsy specimens. The cases included in the study are summarized in ❚Table 1❚. Tumor types included MPNST (n = 24); dedifferentiated liposarcoma (DDLPS) (n = 19); schwannoma (n = 19); solitary fibrous tumor (n = 16); melanoma (n = 15); leiomyosarcoma (n = 15); synovial sarcoma (n = 12); sarcomatoid carcinoma (n = 12); gastrointestinal stromal tumor, spindle cell type (n = 11); desmoid fibromatosis (n = 10); low-grade fibromyxoid sarcoma (n = 7); and unclassified spindle cell sarcoma/undifferentiated pleomorphic sarcoma (n = 20). Specimens were reviewed to assess for adequate cellularity, and diagnoses were confirmed by widely accepted criteria, including review of immunohistochemical results, subsequent surgical excision, and/or molecular/genetic confirmation when applicable. Of the 24 MPNST cases, clinical information was available for 23 cases regarding history of NF1 and the anatomic site of the biopsy, and additional autopsy or surgical specimen follow-up data were available for 21 cases.
Immunohistochemistry was performed on 4-μm formalin-fixed, paraffin-embedded sections after deparaffinization at 42°C. Antigen retrieval was performed using citrate buffer (pH 6.0) in a pressure cooker. Slides were incubated with an antibody against H3K27me3 (1:500, C36B11; Cell Signaling Technology, Danvers, MA) followed by Envision+ horseradish peroxidase reagent (Dako, Carpinteria, CA). As a positive control, an MPNST with known loss of H3K27me3 was stained in parallel, and intact expression of H3K27me3 in endothelial cells and lymphocytes served as internal controls.
Similar to previous work, 26 nuclear H3K27me3 staining was scored as "lost" when more than 95% of tumor cells showed loss of nuclear staining, "partial loss" when 5% to 95% of tumor cells showed loss of nuclear staining, and "retained" when less than 5% of tumor cells showed loss of H3K27me3. For the purposes of data analysis, GIST, gastrointestinal stromal tumor;
LGFMS, low-grade fibromyxoid sarcoma; MPNST, malignant peripheral nerve sheath tumor; USCS/UPS, unclassified spindle cell sarcoma/undifferentiated pleomorphic sarcoma.
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Results
The clinicopathologic features of the 24 cases of MPNST are provided in ❚Table 2❚. Eight (1/20) , and sarcomatoid carcinoma (1/12). The extent of partial loss of H3K27me3 ranged greatly among and within tumor types. Cases of MPNST showed partial loss of H3K27me3 in 20% to 80% of lesional cells, while morphologic mimics showed partial loss ranging from 20% of cells in a case of melanoma to greater than 90% in several cases of synovial sarcoma. As PRC2 complex members have not been reported to have mutations in most of these tumor types, all cases were reviewed and confirmed to have suitable internal controls with the exception of four cases of DDLPS. These four cases were noted to have weak or incomplete (eg, staining in lymphocytes but not endothelial cells) internal controls. Repeat immunohistochemistry for H3K27me3 showed improved internal controls in all four cases and confirmed partial loss of H3K27me3 ❚Image 6A❚ and ❚Image 6B❚. Heterogeneous staining patterns in cases of MPNST have been linked to molecular alterations in PRC2 complex members. 26 As loss-of-function mutations in PRC2 complex genes have not been previously described in DDLPS, we sought to verify this staining pattern in subsequent surgical specimens that were available in three of these cases. All three cases showed retained H3K27me3 ❚Image 6C❚ and ❚Image 6D❚ without any evidence of partial loss of H3K27me3 in the representative section selected for testing.
Discussion
The diagnosis of MPNST on FNA or core biopsy is frequently challenging as the morphologic features and immunohistochemical profile are often not specific. In this study, we examined the utility of H3K27me3 immunohistochemistry as an ancillary test for the diagnosis of MPNST on FNA cell block and small biopsy specimens. In our cohort, 54% of MPNSTs, compared to only 1.3% of non-MPNST cases, showed complete loss of H3K27me3. Similar to previous studies, 24, 26 we have demonstrated that complete loss of H3K27me3 is modestly sensitive (54.2%) but highly specific (98.7%) for MPNST (positive predictive value, 86.7%; negative predictive value, 93.3%). However, it should be noted that in one MPNST showing complete loss of H3K27me3 on core needle biopsy specimen, the subsequent excision specimen was also stained for H3K27me3 and showed focally retained H3K27me3 with associated focal expression of S100 and SOX10, confirming the diagnosis of MPNST. Nonetheless, this raises the possibility of sampling error when evaluating loss of H3K27me3 and suggests that this localized pattern of retained H3K27me3 staining within a tumor may be associated with MPNST, in contrast to the heterogeneous (mosaic) staining observed in the cases showing partial loss within our study. Only two non-MPNST cases showed complete loss of H3K27me3. One of these cases was an FNA from a metastatic sarcomatoid squamous cell carcinoma of the head and neck. Although molecular data are not available for this case, rare examples of head and neck squamous cell carcinoma have been shown to harbor deletions involving PRC2 components EED or EZH2. 27 In addition, although no such association has been made in patients with squamous cell carcinoma of the head and neck, loss of H3K27me3 in several carcinomas has been linked to worse outcomes. 28 Most cases of sarcomatoid carcinoma can be recognized by immunohistochemistry for keratins.
The second non-MPNST case showing complete loss of H3K27me3 was an FNA of an unclassified spindle cell sarcoma. A broad immunohistochemical panel was applied during the initial workup of this case, including S100 and GFAP, which were both negative. However, examination of the cell block specimen showed areas of perivascular accentuation of tumor cells (Image 4C) and focal MDM2 staining that was noted in the initial workup. 29 This constellation of findings, when combined with complete loss of H3K27me3 (Image 4D), argues for a diagnosis of MPNST. This case suggests that a subset of unclassified spindle cell sarcomas may represent unrecognized cases of MPNST. Prior studies examining H3K27me3 in larger cohorts of MPNST found more than 90% of radiation-associated MPNSTs, 24, 26 20% of unclassified radiation-associated sarcomas, 24 and a small subset (3%) of unclassified sarcomas 25 had complete loss of H3K27me3. These findings suggest that H3K27me3 should be part of the immunohistochemical workup of all difficult to classify sarcomas arising in a prior radiation field and suggest that otherwise unclassifiable sarcomas with suggestive cytomorphologic features should also be stained for H3K27me3.
We observed a high rate of partial loss of H3K27me3 in both MPNST (12.5%) and non-MPNST (14.7%) cases. This staining pattern had been recognized in a small subset of MPNSTs and unclassified radiation-associated sarcomas, although at varying cutoffs. 24, 26 In contrast to these studies, we included a diverse group of cytomorphologic mimics of MPNST that may be specifically considered on ❚Image 2❚ Immunohistochemistry for trimethylation of lysine 27 of histone H3 (H3K27me3) is a specific marker for a malignant peripheral nerve sheath tumor (MPNST). A cell block preparation from an MPNST (A, H&E) showed (B) complete loss of H3K27me3 with retained staining in endothelial cells and lymphocytes. Similar results were observed in core biopsy specimens (C, H&E) showing (D) complete loss of H3K27me3.
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Mito et al / H3K27me3 Loss in mPnsT smaLL BioPsy sPecimens FNA, including schwannoma, monophasic synovial sarcoma, DDLPS, leiomyosarcoma, melanoma, and others with partial loss of H3K27me3 as defined by 5% to 95% negative tumor cell nuclei (Table 2) . Among these cases, 15% to 20% of the S100-positive non-MPNST cases (schwannoma and melanoma) showed partial loss of H3K27me3-demonstrating a potential pitfall for overinterpreting partial loss of H3K27me3.
A particularly high proportion of monophasic synovial sarcomas (5/12; 41.7%) showed partial loss of H3K27me3. A study by Cleven and colleagues 25 examining H3K27me3 in MPNST and histologic mimics identified complete loss of H3K27me3 in 60% of synovial sarcomas. In contrast to their study, we and Prieto-Granada et al 26 did not observe complete loss of H3K27me3 in any synovial sarcomas. However, given the heterogeneous staining we observed in a significant subset of monophasic synovial sarcomas, it is quite likely that sampling in the tissue microarrays used in Cleven et al 25 may account for the complete loss of H3K27me3 that was not seen in our study or previous work. 24, 26 Synovial sarcoma is a frequent mimic of MPNST that can be distinguished by immunohistochemistry for EMA and diffuse nuclear TLE1 expression, or confirmation of SS18 gene rearrangement as a subset of MPNST can show TLE1 positivity.
It is likely that the high rate of partial loss of H3K27me3 observed in our study is multifactorial. Prior studies used a polyclonal antibody against H3K27me3 with the monoclonal antibody used in this and one prior study. 26 We also used a mixture of FNA cell block and small biopsy specimens that introduce differences in tissue fixation and processing compared with larger surgical specimens, which may account for changes in immunogenicity. However, the proportion of cases showing partial loss of H3K27me3 that were cell blocks (8/22; 36.4%) was similar to the overall proportion of cell block cases within our study cohort (66/180; 36.7%), arguing against differences in tissue processing as an explanation for the increased number of cases with partial loss of H3K27me3. Finally, although we do not have molecular data to support this, the partial loss of H3K27me3 seen in several tumor types may represent unrecognized biologic heterogeneity within tumors as recent work has suggested intratumoral epigenomic heterogeneity. 30 If this is the case, future work may reveal new mechanisms regulating PRC2 and H3K27me3 that may account for these findings and elucidate biologic functions underling such heterogeneity.
In our study, we identified a group of four DDLPSs that initially were thought to have lost H3K27me3. Re-review of these cases demonstrated weak or incomplete internal controls, typically only in lymphocytes but not endothelial cells. H3K27me3 staining was repeated in these cases with improved intensity, including internal controls, and partial loss of H3K27me3 was identified in tumor cells (Images 6A and 6B) from all four cases. Three of these four cases were core biopsy specimens with subsequent surgical specimens showing associated well-differentiated liposarcoma, MDM2 and CDK4 expression, and/or cytogenetic studies demonstrating 12q13-15 amplification, confirming the diagnosis of DDLPS. To our knowledge, no previous evidence of loss-of-function mutations in PRC2 components has been reported in DDLPS. Thus, to confirm the biopsy findings, we retrieved tissue blocks from subsequent surgical cases for the three DDLPS cases with available material and demonstrated H3K27me3 was retained in all three cases. These results underscore the need to carefully examine specimens for a strong internal control (endothelial cells and lymphocytes) and cautions against interpreting anything less than complete loss of H3K27me3 as supporting a diagnosis of MPNST.
Although previous studies have examined H3K27me3 as a marker for MPNST, none have examined such a broad panel of morphologic mimics of MPNST using a more recently developed monoclonal antibody or examined H3K27me3 in FNA cell block specimens. Complete loss of H3K27me3 is a highly specific (98.7%) but only modestly sensitive (54.2%) marker for MPNST. In contrast to prior work, a significant proportion of MPNST (12.5%) and non-MPNST (14.7%) cases had partial loss of H3K27me3. Our findings suggest that only complete loss of H3K27me3 ❚Image 6❚ Several cases of (A) dedifferentiated liposarcoma showed (B) partial loss of H3K27me3 on biopsy specimens that was not observed in (C) subsequent surgical material that showed (D) retained H3K27me3. (A-D, ×200.)
